The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients

Schizophrenia Clinical Trial

Official title:

The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients Applying to Community Mental Health Center on Alexithymia and Emotion Expression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05662137
• Other study ID #: sinopUadeviye-1
• Status: Completed
• Phase: N/A
• Start date: January 15, 2023
• Est. completion date: May 15, 2023

Study information

• Verified date: October 2023
• Source: Sinop University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As a result of the positive and negative symptoms that occur in schizophrenia, patients with schizophrenia may experience negative emotions more frequently than individuals with other mental problems. Since these emotions can trigger psychotic symptoms, there is a need to develop effective emotion regulation strategies to be applied to patients with schizophrenia. Aim: In this study, it was aimed to examine the effect of emotion recognition and expression program on alexithymia and emotion expression in patients with schizophrenia.

Description:

Method: Fifty schizophrenic patients who regularly receive outpatient treatment at Sinop Community Mental Health Center will form the universe of the study. Individuals over the age of 18 who have schizophrenia, do not have mental retardation, have no comprehension and hearing problems, have insight, and are in remission will be included in the study. Individuals who meet the study criteria will be divided into experimental and control groups as 22 experimental and 22 control groups. The emotion recognition and expression program prepared by the researchers in line with the literature will be applied to the experimental group for 8 weeks. Personal Information Form, Expression of Emotions Scale, Positive and Negative Syndrome Scale and Toronto Alexithymia Scale were planned to be applied to the experimental and control groups in the pre-test, post-test and follow-up. Follow-up will take place one month after the last session of the study. Psychosocial interventions applied to patients with schizophrenia help patients to increase their level of well-being and quality of life, to decrease negative and positive symptoms by increasing social functionality, to participate in social life, to be an autonomous individual and to prevent stigma. In line with psychosocial interventions, it is thought that the this program to be applied to the patients in this study will basically contribute to the individual patients' ability to recognize their emotions, discuss their emotions, regulate their emotion intensities, and express their emotions. Due to the impact that this program will have on the individual, it is believed that it will have positive results not only for schizophrenia patients, but also for the individuals with whom the patients interact, their relatives and even the society.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: May 15, 2023
• Est. primary completion date: May 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patient who had received a diagnosis of schizophrenia and comes to the Community Mental Health Center regularly,
• Being able to read and communicate
• Being 18 years of age or older,
• Not having mental retardation,
• Not having insight, understanding, hearing problems,
• Being in remission,
• Volunteering to study

Exclusion Criteria:

• Not diagnosed with clinical schizophrenia,
• Being under the age of 18,
• Having mental retardation,
• Having no insight,
• Not understanding and hearing,
• Not in remission
• Refusing to participate in the study
• Stop studying at any stage of the study

Related Conditions & MeSH terms

• Affective Symptoms
• Alexithymia
• Emotion, Expressed
• Schizophrenia

Intervention

Behavioral:
• Emotions Recognition and Expression
Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.

Locations

Country	Name	City	State
Turkey	Sinop Community Mental Health Center	Sinop

Sponsors (1)

Lead Sponsor	Collaborator
Sinop University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Emotion Recognition and Expression	Expression of Emotions Scale is used to measure the state of expression of emotions. The scale was developed by King and Emmons (1990), and its Turkish validity and reliability were verified by Kuzucu (2011). The measurement tool consists of a total of 16 items and 3 sub-dimensions. It has positive, negative and closeness sub-dimensions. It is a 7-point Likert type scale .The scores to be taken from the scale vary between 15 and 105, and as the scores obtained increase, it is seen that the tendency of the individual to express emotion increases. The scale provides information about expressing emotions both in interpersonal relationships and independent of interpersonal relationships. A high score indicates a high tendency to express emotions.	One day
Primary	Alexithymia	Toronto Alexithymia Scale (TAS): The scale was developed by Bagby et al. (1994) Güleç et al. (2009) adapted into Turkish. The scale consists of 20 items, has three sub-dimensions and is in a 5-point Likert type. High scores indicate high alexithymic level. There are sub-dimensions of difficulty in recognizing emotions, difficulty in putting emotions into words, and extroverted thinking.	One day
Primary	Positive and Negative Syndrome	Positive and Negative Syndrome Scale (PANNS): The scale evaluating positive and negative symptoms in schizophrenia was developed by Kay et al (1987) and Kostakoglu et al. It was adapted into Turkish by (1999). Consisting of 30 items, the scale has three sub-dimensions. A 7-point severity assessment is carried out. Seven of the items of the scale belong to the positive symptoms subscale, seven to the negative symptoms subscale, and the remaining sixteen to the general psychopathology subscale.	One day